This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The two companies — through their respective subsidiaries — have entered into a strategic agreement that aims to accelerate the generation of high-caliber clinical data for TEV-56278 while extending its reach to patients across geographies with high unmet medical need.
The strategic funding arrangement is designed to support the continued advancement and global commercialization of Revolution Medicines’ RAS(ON) inhibitor portfolio, including its lead candidate daraxonrasib, as the company scales its operations independently across the international oncology market.
Internally, the models learn to associate concepts, find patterns and relate text and images (or other modalities) so that they can be analysed in the same way. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes.
To date, more than 70 joint research projects have been initiated, and over 10 co-authored publications have appeared in top-tier international academic journals. A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors.
One of the most significant challenges in drug development is global regulatory variability. While international agencies strive for harmonization through organizations such as the International Council for Harmonisation (ICH), regulatory frameworks differ significantly across regions.
Donello was most recently Vice President of External Science & Innovation at Allergan/AbbVie, where he led R&D innovation efforts to develop strategic collaborations, in-licenseclinical-stage assets and evaluate M&A opportunities.
The leading clinical program had been the ADC patritumab deruxtecan (HER3-DXd) targeting HER3 and carrying a topoisomerase I inhibitor payload (Topo1i, the drug conjugate) attached using a cleavable linker. Clinicaldevelopment is extensive, as detailed by @ByMadeleineA at ApexOnco ( [link] ; [link] ).
A final lipophilicity adjustment led to the discovery of CDZ173 (leniolisib), a potent PI3K selective inhibitor with suitable properties and efficacy for clinicaldevelopment as an anti-inflammatory therapeutic. Jump up to: a b c d e f “Joenja- leniolisib tablet, film coated” DailyMed. 29 March 2023. Retrieved 20 June 2023.
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of diarrhoeal disease and death in children under five by licensing its Shigella vaccine candidate, altSonflex1-2-3 , to Bharat Biotech International Limited (BBIL).
Here are some key strategies: File early and often Pursue multiple patent types Consider international patent protection Continuously innovate and file improvement patents By implementing these strategies, you can create a web of protection that’s difficult for competitors to navigate around.
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).
million and US$1.8
1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). .
TOKYO and CAMBRIDGE, England , Dec. GPCR – G protein-coupled receptors.
26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. BioInvent International AB (publ).
Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy. These compounds were later licensed to the pharmaceutical industry for clinicaldevelopment.
9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB :s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed. Proposals to the Nomination Committee can be sent to Stefan Ericsson , by mail: BioInvent International AB (publ).), BioInvent International AB (publ).
There is a continuum of evidence for a given target – at one end are novel targets with some evidence of importance in disease, and at the other end are “de-risked” targets where the biology is precedented with an approved product or late-stage clinical asset(s). asset has not been de-prioritized due to safety or efficacy)?
Due to internal hydrogen bonding, DELAQ is a linear, nonionized metabolite with a LogP of roughly 7. Figure 2: Internal hydrogen bonding of DELAQ In contrast to laquinimod, DELAQ is a very potent activator of the aryl hydrocarbon receptor (AhR). Studies in non-clinical species raised no obvious red flags of this clinical outcome.
These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need.
Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinicaldevelopment for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.
BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with three ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. LUND, Sweden , Jan.
The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Join the club.
ET ) to discuss the results and next steps in clinicaldevelopment of BI-1206. Subjects who show clinical benefit at week 6 continue onto maintenance therapy and receive BI-1206 and rituximab once every 8 weeks for up to 6 maintenance cycles, or up to 1 year from first dose of BI-1206.
(Nasdaq: CASI), a U.S.
The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. Sosei Heptares will now conduct a full internal review to determine a strategy for the further development and re-partnering of the program. ” About the License Agreement. TOKYO and CAMBRIDGE, England , Jan.
HK) is a global, clinicaldevelopment stage, biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and immunologic diseases. Harbour BioMed also licenses the platforms to companies and academic institutions. .” he added. About Harbour BioMed. Harbour BioMed (HKEX: 02142.HK)
27, 2020 /PRNewswire/ — BioInvent International AB ‘s (publ) (“BioInvent”) (OMXS: BINV) Extraordinary General Meeting (the “EGM”) today resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.
This is due to concurrent processes with the European Medicines Agency (EMA) and national pricing and reimbursement procedures, leading to competition for internal resources within pharmaceutical companies. PICO challenges and opportunities One of the main challenges lies in the uncertainties regarding the timelines for PICO scoping.
It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. Now, as part of AbbVie, the program is well positioned to move into later stages of clinicaldevelopment.” The company has also benefited from support from the Walloon Region. Source link: [link].
International Dial-in Number: (210) 874-7715. ELX-02 is in the early stages of clinicaldevelopment focusing on cystic fibrosis. Conference Call Information : Date : Thursday, November 5, 2020. Time : 4:30 p.m. Domestic Dial-in Number : (866) 913-8546. Conference ID : 9467336.
7 Implementing an international differentiated pricing strategy specifically designed to address needs during this pandemic and improve affordability.7 The extensive Actemra/RoActemra RA intravenous (IV) clinicaldevelopment programme included five phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries.
This, along with our other partnerships and internal programs, reflects Gilead’s commitment to continuing innovation to discover a cure for HIV and bring about an end to the HIV epidemic.”. “We Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.
Now, a large international study, partly funded by NIH, offers some good news: proof-of-principle that “Big Data” tools can help to identify a drug’s potential side effects much earlier in the drug development process [2]. 5] Clinicaldevelopment success rates for investigational drugs. 2012 Jul 6;337(6090):100-104. [4]
our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales in the U.S.
The Company anticipates using net proceeds from the offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. Morgan Securities LLC, Goldman Sachs & Co.
“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck Research Laboratories. About Pneumococcal Disease.
According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA).
Vertex and Ono Pharmaceutical Forge Strategic Partnership to Develop and Commercialize Povetacicept in Japan and South Korea In a move that underscores the growing international collaboration in advancing treatment for autoimmune and kidney-related diseases, Vertex Pharmaceuticals Incorporated and Ono Pharmaceutical Co.,
AstraZeneca , with Alexion ‘s R&D team, will work to build on Alexion ‘s pipeline of 11 molecules across more than 20 clinical-development programmes across the spectrum of indications, in rare diseases and beyond. Click here for available international numbers. UK : +44 203 481 5237. Sweden : +46 8 5052 0017.
“Building on Pfizer’s established leadership position in breast cancer science and CDK 4/6 inhibition, we are excited to work with Arvinas to maximize ARV-471, the first PROTAC for breast cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer,” said Jeff Settleman, Ph.D.,
Now poised to advance a robust therapeutics pipeline to clinicaldevelopment, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. RayzeBio is also funneling cash into expanding its HQ in San Diego with plans to further developinternal R&D. .
The IOC and International Paralympics Committee (IPC) have made it clear that vaccination is not mandatory in order for athletes to participate in the Olympic and Paralympic Games, and that any vaccination program must be conducted in full respect of national vaccination priorities.
We have done this by both internal talent development as well as by external hires. 10% of its Net Sales in R&D and also invests significantly in business development and in-licensing. Tirbanibulin is a topical drug for the treatment of actinic keratosis in adult patients developed by Athenex and licensed by Almirall.
Amgen’s clinicaldevelopment team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C ?inhibitor Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected.
This allows us to compress preclinical development and go directly into proof-of-concept Phase 2 studies. It also has significant positive impacts on our clinicaldevelopment timelines and de-risks the development of new CNPs.
Postapproval manufacturing changes for biological products During clinicaldevelopment or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content